Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the
efficacy of Surufatinib 300 mg once a day in treating advanced extrapancreatic neuroendocrine
tumors.